Nasus Pharma (NSRX) releases updated February 2026 corporate presentation

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

6-K

Rhea-AI Filing Summary

Nasus Pharma Ltd. submitted a report stating that it has made an updated corporate presentation available on its website in February 2026. The presentation, dated February 2026, is attached as Exhibit 99.1. The company clarifies that this material is not a prospectus or offering document and should not be treated as an offer to sell or buy any securities, or as the basis for any related contract or commitment.

Form 6-K: How Foreign Companies Report to the SEC →

02/23/2026 - 08:53 PM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of February 2026 (Report No. 3)

Commission File Number: 001-42796

Nasus Pharma Ltd.

Yigal Alon 65

Tel Aviv, Israel 6744317

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

CONTENTS

On February 23, 2026, Nasus Pharma Ltd. (the “Company”) made available an updated corporate presentation on its website. A copy of the corporate presentation is attached hereto as Exhibit 99.1 to this Report of Foreign Private Issuer on Form 6-K.

The information contained in the corporate presentation does not constitute a prospectus or other offering document, nor does it constitute or form part of any invitation or offer to sell, or any solicitation of any invitation or offer to purchase or subscribe for, any securities of the Company or any other entity, nor shall the information or any part of it or the fact of its distribution form the basis of, or be relied on in connection with, any action, contract, commitment or relating thereto or to the securities of the Company.

EXHIBIT INDEX

Exhibit No.		Description
99.1		Corporate Presentation, dated February 2026.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	NASUS PHARMA LTD.

Date: February 23, 2026	By:	/s/ Dan Teleman
	Name:	Dan Teleman
	Title:	Chief Executive Officer

Exhibit 99.1

Source: View Original Filing on SEC EDGAR

FAQ

What did Nasus Pharma Ltd. (NSRX) report in this February 2026 6-K?

Nasus Pharma reported that it made an updated corporate presentation available on its website. The presentation, dated February 2026, is attached as Exhibit 99.1 and provides additional company information for interested stakeholders.

Does the Nasus Pharma (NSRX) February 2026 corporate presentation represent an offering of securities?

No, the corporate presentation explicitly does not constitute a prospectus or offering document. It is not an invitation or offer to sell, purchase, or subscribe for any securities of Nasus Pharma Ltd. or any other entity.

When was the Nasus Pharma (NSRX) updated corporate presentation made available?

Nasus Pharma made the updated corporate presentation available on February 23, 2026. The presentation is dated February 2026 and is attached to the report as Exhibit 99.1 for reference.

What is included as Exhibit 99.1 in Nasus Pharma’s (NSRX) February 2026 report?

Exhibit 99.1 contains Nasus Pharma Ltd.’s updated corporate presentation dated February 2026. This exhibit consolidates the information made available on the company’s website for investors and other interested parties.

Can investors rely on the Nasus Pharma (NSRX) corporate presentation as the basis for investment contracts?

The company states that the information in the presentation should not be relied upon as the basis for any action, contract, or commitment relating to Nasus Pharma’s securities. It is informational and not a transactional document.

Filing Exhibits & Attachments

68 documents